Sector News

Cardinal Health buys Medtronic units for $6B

April 19, 2017
Life sciences

Cardinal Health said Tuesday it had agreed to acquire Medtronic’s medical supplies units for $6.1 billion but shares of the medical device giant plunged on a forecast for fiscal 2017 earnings that was at the low end of its earlier guidance.

Medtronic’s patient care, deep vein thrombosis and nutritional insufficiency units span 23 product categories across multiple markets, including brands such as Curity, Kendall, Dover, Argyle and Kangaroo that are used in nearly every U.S. hospital. They generated about $2.4 billion in revenue in the last four reported quarters.

The deal will expand Cardinal’s growing medical products business.

“Given the current trends in healthcare, including aging demographics and a focus on post-acute care, this industry-leading portfolio will help us further expand our scope in the operating room, in long-term care facilities and in home healthcare, reaching customers across the entire continuum of care,” Cardinal CEO George S. Barrett said in a news release.

Analysts also cheered the move. “We believe [the acquisition] fits well into Cardinal Health’s strategy in medical, and continues to diversify the business away from pharma distribution,” Cowen & Co.’s Charles Rhyee wrote.

Cardinal expects the acquisition to be accretive to non-GAAP diluted earnings per share by more than $0.55 per share in fiscal 2019, and increasingly accretive thereafter.

But the company also announced Tuesday that it expects fiscal 2017 earnings per share at the low end of earlier guidance of $5.35 to $5.50 per share, compared with the FactSet consensus of $5.42. It cited generic price deflation in its pharmaceutical business.

In trading Tuesday, Cardinal shares dropped 11.5% to $72.39. The stock had jumped 8.0% over the past three months, compared to a 3.4% rise in the S&P 500.

“The weaker guidance, which includes the positive accretion from Medtronic’s supply business, is concerning for the distributor sector,” Mizuho Securities USA analyst Ann Hynes told Reuters.

Cardinal said it will fund the Medtronic deal with $4.5 billion in new debt plus existing cash. That prompted Fitch Ratings to express concerns over Cardinal’s debt burden and lower its outlook on the company.

By Matthew Heller

Source: CFO

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach